Natera (NTRA) announced the next phase of proceedings in its patent infringement litigation against CareDx (CDNA). The U.S. District Court for the District of Delaware will now determine if CareDx owes a royalty for future infringement related to ongoing and future AlloSure testing occurring after August 2023. This follows a Jan. 2024 jury verdict in favor of Natera, in which the jury awarded $96.3M in damages to Natera in lost profits and past royalties through August 2023. The jury found that CareDx’s AlloSure and AlloSeq tests infringed one of the two Natera patents asserted against CareDx and that all asserted claims of both patents are valid on various grounds. Discovery and briefing for this next phase are expected to last through the end of summer 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NTRA:
- Medicare extends coverage of Natera’s signatera MRD test to ovarian cancer
- NTRA Earnings this Week: How Will it Perform?
- Natera downgraded to Outperform from Strong Buy at Raymond James
- Jury rules in favor of Natera in patent infringement lawsuit against CareDx
- CareDx found to have not infringed on one Natera patent, infringed on another
